Compositions for treating chronic inflammation and inflammatory diseases

Patent metadata

Field	Value
Publication number	US-9271950-B2
Application number	US-201414155042-A
Country	US
Kind code	B2
Filing date	Jan 14, 2014
Priority date	Oct 29, 2010
Publication date	Mar 1, 2016
Grant date	Mar 1, 2016

Abstract

The present specification discloses pharmaceutical compositions, methods of preparing such pharmaceutical compositions, and methods and uses of treating a chronic inflammation and/or an inflammatory disease in an individual using such pharmaceutical compositions.

First claim

The invention claimed is:

1. A pharmaceutical composition comprising:
a) about 10% to 30% of a non-steroidal anti-inflammatory drug (NSAID) by weight of the pharmaceutical composition;
b) about 5% to about 15% of a polyethylene glycol (PEG) polymer by weight of the pharmaceutical composition;
c) about 20% to about 50% of a hard fat by weight of the pharmaceutical composition; and
d) about 10% to about 30% of a polyether fatty acid ester by weight of the pharmaceutical composition,

wherein the pharmaceutical composition is formulated to be a solid at a temperature of about 15° C. or lower and have a melting point temperature in the range of about 25° C. or higher.

2. The pharmaceutical composition according to claim 1 , wherein the NSAID is about 20% to about 30% by weight of the pharmaceutical composition.

3. The pharmaceutical composition according to claim 2 , wherein the NSAID is in an amount from about 25% to about 30% by weight of the pharmaceutical composition.

4. The pharmaceutical composition according to claim 1 , wherein the NSAID is a non-selective cyclo-oxygenase (COX) inhibitor, a selective cyclooxygenase 1 (COX 1) inhibitor, a selective cyclooxygenase 2 (COX 2) inhibitor or a combination thereof.

5. The pharmaceutical composition according to claim 3 , wherein the NSAID comprises a salicylate derivative NSAID, a p-amino phenol derivative NSAID, a propionic acid derivative NSAID, an acetic acid derivative NSAID, an enolic acid derivative NSAID, a fenamic acid derivative NSAID or a combination thereof.

6. The pharmaceutical composition according to claim 5 , wherein the propionic acid derivative NSAID comprises an Alminoprofen, a Benoxaprofen, a Dexketoprofen, a Fenoprofen, a Flurbiprofen, an Ibuprofen, an Indoprofen, a Ketoprofen, a Loxoprofen, a Naproxen, an Oxaprozin, a Pranoprofen, or a Suprofen.

7. The pharmaceutical composition according to claim 6 , wherein the propionic acid derivative NSAID is a pharmaceutically-acceptable form of an Ibuprofen.

8. The pharmaceutical composition according to claim 1 , wherein the hard fat is in an amount from about 30% to about 50% by weight of the pharmaceutical composition.

9. The pharmaceutical composition according to claim 8 , wherein the hard fat is in an amount from about 35% to about 45% by weight of the pharmaceutical composition.

10. The pharmaceutical composition according to claim 8 , wherein the hard fat has a melting point of about 40° C. to about 46° C.

11. The pharmaceutical composition according to claim 8 , wherein the hard fat comprises a triglyceride or a triester of glycerol.

12. The pharmaceutical composition according to claim 11 , wherein the triglyceride comprises a mixture of saturated C 10 -C 18 triglycerides having a melting point of between 41° C. to 45° C.

13. The pharmaceutical composition according to claim 12 , wherein the triglyceride comprises a mixture of saturated C 10 -C 18 triglycerides having a melting point of about 43° C.

14. The pharmaceutical composition according to claim 1 , wherein the polyether fatty acid ester is in an amount from about 15% to about 25% by weight of the pharmaceutical composition.

15. The pharmaceutical composition according to claim 14 , wherein the polyether fatty acid ester comprises a mono-fatty acid ester of a polyether, a di-fatty acid ester of a polyether, or a tri-fatty acid ester of a polyether, or any combination thereof.

16. The pharmaceutical composition according to claim 15 , wherein the polyether fatty acid ester is glyceryl monolinoleate.

17. The pharmaceutical composition according to claim 1 , wherein the PEG polymer is in an amount from about 8% to about 15% by weight of the pharmaceutical composition.

18. The pharmaceutical composition according to claim 17 , wherein the PEG polymer is in an amount from about 7% to about 13% by weight of the pharmaceutical composition.

19. The pharmaceutical composition according to claim 18 , wherein the pharmaceutically-acceptable PEG polymer is in an amount from about 8% to about 12% by weight of the pharmaceutical composition.

20. The pharmaceutical composition according to claim 19 wherein the PEG polymer is in an amount from about 9% to about 11% by weight of the pharmaceutical composition.

21. The pharmaceutical composition according to claim 1 , wherein the PEG polymer is a liquid PEG polymer.

22. The pharmaceutical composition according to claim 21 , wherein the pharmaceutically-acceptable PEG polymer is less than about 2,000 g/mol.

23. The pharmaceutical composition according to claim 22 , wherein the liquid PEG polymer is a PEG 100, a PEG 200, a PEG 300, a PEG 400, a PEG 500, a PEG 600, a PEG 700, a PEG 800, a PEG 900, a PEG 1000, or a combination thereof.

Assignees

• Infirst Healthcare Ltd

Inventors

• Bannister Robin M
• Brew John
• Caparros-Wanderely Wilson
• Dilly Suzanne J
• Pleguezeulos Mateo Olga
• Stoloff Gregory A

Classifications

• A61K47/14 Primary

  Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters · CPC title

• A61K31/25

  with polyoxyalkylated alcohols, e.g. esters of polyethylene glycol · CPC title

• A61K31/202

  having three or more double bonds, e.g. linolenic (eicosanoids, e.g. leukotrienes A61K31/557) · CPC title

• A61K31/19

  Carboxylic acids, e.g. valproic acid (salicylic acid A61K31/60) · CPC title

• A61K9/08

  Solutions {(composition of solutions A61K47/00)} · CPC title